Clinical Trial Results:
A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk markers in subjects with Type 2 diabetes treated with metformin who have not achieved target HbA1c
Summary
|
|
EudraCT number |
2004-000577-65 |
Trial protocol |
FI |
Global completion date |
03 Dec 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jan 2019
|
First version publication date |
04 Jan 2019
|
Other versions |
|
Summary report(s) |
GWAR Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.